Resverlogix Board of Directors Update

Calgary, Canada (ots/PRNewswire) -

- Provides Shareholders With an Update on Strategic Review
Activities

On behalf of Resverlogix Corp. ("Resverlogix" or the "Company")
(TSX:RVX) the Board of Directors, due to the recent advancement of
various discussions with third parties, feel it is prudent to update
the market as to activities surrounding a previously announced
strategic review process of January 25, 2007. One strategic review
option currently under evaluation by the Company is an offer to
out-license the Company's NexVas(TM) PR technology for cardiovascular
indications to a single Asian country in order to generate non
dilutive equity while continuing to further the development of our
cardiovascular programs. As a result of the progression of term
discussions with more than one Asian pharmaceutical group in this
regard, the Board has directed management to proceed with the option
for a one country licensing deal concurrently with global deal
discussions. To this end, Resverlogix has received a mutually
acceptable non-binding proposal for the licensing of NexVas PR and
will seek to further advance negotiations. No time frame or terms
will be released at this time as there is currently no guarantee that
this process will result in a completed licensing deal.

The Board of Directors is also pleased to update shareholders on
the ongoing strategic review process pertaining to various types of
global partnership deals relating to the NexVas PR technology.
Currently, there are three global pharmaceutical companies who are in
the process of performing extensive due diligence on NexVas PR and
other Resverlogix technologies. Management is also in ongoing
discussion with numerous other groups that have shown interest in the
NexVas PR technology. The Board is cautious to add that any potential
transactions are subject to an extensive negotiation process and
there can be no assurance that they will be finalized or that they
will result in any specific transaction that will be acceptable to
the Company. Management and the Board of Directors will continue to
monitor ongoing developments and update the market when deemed
appropriate or required.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I production within one's own body. These vital
therapies address the grievous burden of atherosclerosis and other
important diseases such as acute coronary syndrome, diabetes,
Alzheimer's disease and other vascular disorders. The Company's
secondary focus is TGF-Beta Shield(TM), a program that aims to
address burgeoning grievous diseases, such as cancer and fibrosis.
Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For
further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information:
Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: +1-604-538-7072
Email: Theresa@resverlogix.com
Sarah Zapotichny
Manager, Investor Relations
Resverlogix Corp.
Phone: +1-403-254-9252
Email: Sarah@resverlogix.com
Website: http://www.resverlogix.com/

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com